Vitrafy Builds US Blood Network as FDA Device Listing Nears

Three US Blood Partnerships Reach 179 Collection Sites

Vitrafy Life Sciences Limited (ASX:VFY) has broadened its US commercial footprint to approximately 17% of civilian blood collection sites, with partnerships covering about 179 fixed-point locations that collectively handle roughly 2.4 million blood units a year.

The network now includes Vitalant, Hoxworth Blood Center and Versiti Blood Health. The latest agreement, announced on 30 September, will initially place two Guardion cryopreservation devices at Versiti’s Blood Research Institute in Milwaukee, supporting development of no-wash platelet cryopreservation. Versiti will also supply blood products and resources for validation studies covering currently approved cryopreserved products, including plasma. The quarter also advanced the Versiti blood partnership, which was previously described as generating no immediate revenue and remaining subject to US regulatory requirements.

Charter Agreement Extends Guardion Into Cell Therapy

Vitrafy also entered the US cell and gene therapy market through an agreement with Charter Medical. A Guardion device and the company’s LifeChain software will be installed at Charter’s North Carolina Innovation Hub for cryopreservation and freeze-curve optimisation studies for Charter’s customers.

The arrangement creates an opportunity for Vitrafy to demonstrate its technology to therapy developers and manufacturers and explore longer-term commercial relationships. It is an expansion of the company’s addressable market rather than evidence of established commercial revenue from the program; the Charter Medical agreement was previously reported as an initial deployment with no immediate revenue.

FDA Listing Work Moves Toward Mandatory Validation

Vitrafy completed nine Guardion devices during the quarter, with all units intended for existing partners or medical device testing. Six more units are planned for construction in the first half of FY2027, with deliveries scheduled across October and November.

Verification work for the planned US medical device listing is progressing, while mandatory validation studies on blood products are about to begin with an initial focus on plasma. USAISR and Bio Bridge Global are supporting the work. Vitrafy says listing remains on track for the end of 1H FY2027, and its broader outlook targets the end of 2026. Neither milestone has yet been completed.

“Managing Director, Brent Owens, presenting at a seminar hosted at AABB 2026 at which Vitrafy unveiled its new Scientific Advisory Board comprised of global human health experts.”

At the AABB annual meeting in Atlanta, USAISR presented Phase II in-vitro platelet study results showing 94.4% mean post-thaw platelet recovery under a 3% DMSO no-wash protocol. The filing presents that external presentation as third-party validation of the ecosystem, but the result comes from the stated study conditions and does not by itself establish regulatory clearance or commercial adoption.

A$38.3 Million Liquidity Buffer Meets Rising Investment

Vitrafy held A$38.3 million in cash and term deposits at 30 September. The Appendix 4C reported A$23.174 million in cash and cash equivalents, plus a further A$15 million in term deposits classified as short-term investments. Net operating cash outflow was A$4.857 million for the quarter, with customer receipts of A$113,000, government grants and tax incentives of A$328,000, and interest received of A$364,000.

The company’s reported funding calculation shows 4.8 quarters based on cash and unused facilities, rising to 7.9 quarters on a pro forma basis including the additional term deposits. Average monthly cash burn was approximately A$1.9 million, and Vitrafy expects cash costs to increase as it funds validation, US commercial expansion, manufacturing capacity and the initial medical device fleet. The next test is whether those investments convert partnership activity into paid deployments before the additional spending materially shortens the runway.